Cargando…

Major adverse cardiac events and drug-coated balloon size in coronary interventions

OBJECTIVE: In-stent restenosis (ISR) is a feared complication after coronary stent implantation. Drug-coated balloon (DCB) is being promoted as a treatment option for ISR. However, the benefit-risk ratio of DCB length has not been investigated. Longer DCBs release more anti-proliferative drug to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Naguib, David, Knoop, Betül, Dannenberg, Lisa, Liebsch, Eva, Pöhl, Martin, Helten, Carolin, Assadi-Schmidt, Athena, Kelm, Malte, Zeus, Tobias, Polzin, Amin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kare Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998862/
https://www.ncbi.nlm.nih.gov/pubmed/29848922
http://dx.doi.org/10.14744/AnatolJCardiol.2018.67864
_version_ 1783331316396195840
author Naguib, David
Knoop, Betül
Dannenberg, Lisa
Liebsch, Eva
Pöhl, Martin
Helten, Carolin
Assadi-Schmidt, Athena
Kelm, Malte
Zeus, Tobias
Polzin, Amin
author_facet Naguib, David
Knoop, Betül
Dannenberg, Lisa
Liebsch, Eva
Pöhl, Martin
Helten, Carolin
Assadi-Schmidt, Athena
Kelm, Malte
Zeus, Tobias
Polzin, Amin
author_sort Naguib, David
collection PubMed
description OBJECTIVE: In-stent restenosis (ISR) is a feared complication after coronary stent implantation. Drug-coated balloon (DCB) is being promoted as a treatment option for ISR. However, the benefit-risk ratio of DCB length has not been investigated. Longer DCBs release more anti-proliferative drug to the vessel wall; however, they are associated with a higher lesion length and vessel injury. Hypothesis: DCB length is associated with clinical outcome. METHODS: We analyzed 286 consecutive Pantera Lux (Biotronik, active component Paclitaxel) DCB-treated patients between April 2009 and June 2012. Of them, 176 patients were treated using a 15-mm DCB and 109 were treated using a 20-mm DCB. Baseline characteristics and major adverse cardiac events (MACE; death, myocardial infarction, and target lesion revascularization) during initial hospital stay and a 2-year follow-up period were obtained. RESULTS: Patients characteristics such as cardiovascular risk factors, prior diseases, co-medication, clinical presentation, target vessel, and left ventricular function did not differ between the groups. MACE during hospital course was similar [1.7% vs. 2.8%, relative risk (RR) 1.6, 95% confidence interval (CI) 0.3-7.9, p=0.554]. Likewise, at 2-year follow-up, MACE did not differ between the groups (23.2% vs. 27.5%, RR 1.2, 95% CI 0.6-1.5, p=0.408). CONCLUSION: DCB length was not associated with clinical outcome during a 2-year follow-up period.
format Online
Article
Text
id pubmed-5998862
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Kare Publishing
record_format MEDLINE/PubMed
spelling pubmed-59988622018-06-18 Major adverse cardiac events and drug-coated balloon size in coronary interventions Naguib, David Knoop, Betül Dannenberg, Lisa Liebsch, Eva Pöhl, Martin Helten, Carolin Assadi-Schmidt, Athena Kelm, Malte Zeus, Tobias Polzin, Amin Anatol J Cardiol Original Investigation OBJECTIVE: In-stent restenosis (ISR) is a feared complication after coronary stent implantation. Drug-coated balloon (DCB) is being promoted as a treatment option for ISR. However, the benefit-risk ratio of DCB length has not been investigated. Longer DCBs release more anti-proliferative drug to the vessel wall; however, they are associated with a higher lesion length and vessel injury. Hypothesis: DCB length is associated with clinical outcome. METHODS: We analyzed 286 consecutive Pantera Lux (Biotronik, active component Paclitaxel) DCB-treated patients between April 2009 and June 2012. Of them, 176 patients were treated using a 15-mm DCB and 109 were treated using a 20-mm DCB. Baseline characteristics and major adverse cardiac events (MACE; death, myocardial infarction, and target lesion revascularization) during initial hospital stay and a 2-year follow-up period were obtained. RESULTS: Patients characteristics such as cardiovascular risk factors, prior diseases, co-medication, clinical presentation, target vessel, and left ventricular function did not differ between the groups. MACE during hospital course was similar [1.7% vs. 2.8%, relative risk (RR) 1.6, 95% confidence interval (CI) 0.3-7.9, p=0.554]. Likewise, at 2-year follow-up, MACE did not differ between the groups (23.2% vs. 27.5%, RR 1.2, 95% CI 0.6-1.5, p=0.408). CONCLUSION: DCB length was not associated with clinical outcome during a 2-year follow-up period. Kare Publishing 2018-06 2018-05-22 /pmc/articles/PMC5998862/ /pubmed/29848922 http://dx.doi.org/10.14744/AnatolJCardiol.2018.67864 Text en Copyright: © 2018 Turkish Society of Cardiology http://creativecommons.org/licenses/by-nc-sa/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Original Investigation
Naguib, David
Knoop, Betül
Dannenberg, Lisa
Liebsch, Eva
Pöhl, Martin
Helten, Carolin
Assadi-Schmidt, Athena
Kelm, Malte
Zeus, Tobias
Polzin, Amin
Major adverse cardiac events and drug-coated balloon size in coronary interventions
title Major adverse cardiac events and drug-coated balloon size in coronary interventions
title_full Major adverse cardiac events and drug-coated balloon size in coronary interventions
title_fullStr Major adverse cardiac events and drug-coated balloon size in coronary interventions
title_full_unstemmed Major adverse cardiac events and drug-coated balloon size in coronary interventions
title_short Major adverse cardiac events and drug-coated balloon size in coronary interventions
title_sort major adverse cardiac events and drug-coated balloon size in coronary interventions
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998862/
https://www.ncbi.nlm.nih.gov/pubmed/29848922
http://dx.doi.org/10.14744/AnatolJCardiol.2018.67864
work_keys_str_mv AT naguibdavid majoradversecardiaceventsanddrugcoatedballoonsizeincoronaryinterventions
AT knoopbetul majoradversecardiaceventsanddrugcoatedballoonsizeincoronaryinterventions
AT dannenberglisa majoradversecardiaceventsanddrugcoatedballoonsizeincoronaryinterventions
AT liebscheva majoradversecardiaceventsanddrugcoatedballoonsizeincoronaryinterventions
AT pohlmartin majoradversecardiaceventsanddrugcoatedballoonsizeincoronaryinterventions
AT heltencarolin majoradversecardiaceventsanddrugcoatedballoonsizeincoronaryinterventions
AT assadischmidtathena majoradversecardiaceventsanddrugcoatedballoonsizeincoronaryinterventions
AT kelmmalte majoradversecardiaceventsanddrugcoatedballoonsizeincoronaryinterventions
AT zeustobias majoradversecardiaceventsanddrugcoatedballoonsizeincoronaryinterventions
AT polzinamin majoradversecardiaceventsanddrugcoatedballoonsizeincoronaryinterventions